Ecological Screening Assessment Report on Perfluorooctane Sulfonate, Its Salts and Its Precursors that Contain the C8F17SO2 or C8F17SO3, or C8F17SO2N Moiety
- Synopsis
- Introduction
- 1. Identity, Uses, and Sources of Release
- 2. Environmental Fate, Exposure and Effects
- 3. Environmental Concentrations
- 4. Key Toxicological Studies
- 5. Risk Quotient Analyses
- 6. Discussion
- 7. Conclusion
- 8. Reference
- Appendix 1: List of PFOS and its Precursors
- Appendix 2: PFOS Concentrations in Selected Wildlife in North America and Circumpolar Regions, 1982-2005
- Appendix 3: Risk Quotients for Migratory Birds
- Appendix 4: Summary of Data used in Risk Quotient (Q) Analyses of PFOS
- Appendix 5: Risk Quotients for PFOS
Appendix 5: Risk Quotients for PFOS
| Test Organism/ Study Type | Reference | Effect | Critical Effect Level | Concen- tration in Serum (CTV) (mg.L-1 Serum) | Concen- tration in Liver at Critical Effect (CTV) (µg.kg-1 ww Liver) | AFa | ENEV (ug.kg-1 Liver) | EEVb (µg.kg-1 Liver) | Q (EEV/ ENEV) |
|---|---|---|---|---|---|---|---|---|---|
| Rat receiving 0, 0.5, 2, or 5 ppm PFOS-K salt in diet for 104 weeks (2 years) | Covance 2002 | Microscopic changes in liver | LOEL (m/f) = 2.0 ppm diet (0.06 to 0.23 mg.kg-1 bw/d) | 13.9 mg.L-1 | 40800 (40.8 µg.g-1) | 100 | 408 | 3770 | 9.24 |
| Monkeys administered 0.03, 0.15, 0.75 mg.kg-1 bw/d PFOS for 26 weeks | Covance Labs 2002a | Thymic atrophy, reduced serum HDLP, cholesterol, triiodot- yhronine, total bilirubin | LOEL (m/f) = 0.03 mg.kg-1 bw/d | 14.5 mg.L-1 | 19800 (19.8 µg.g-1) | 100 | 198 | 3770 | 19.04 |
2 Generation- rat-F0 F1: 0.1, 0.4 mg.
| Argus Research Lab 2000 #418-008 (also cited as US EPA OPPT AR-226 0569) | F0 males: reduced body weight gains | F0 male: NOEL = 0.1 mg. kg-1 bw/d LOEL = 0.4 mg. kg-1 bw/d | 10.5 mg.L-1 45.4 mg.L-1 | 84900 (84.9 µg.g-1) 176000 (176 µg.g-1) | 10 40 | 8490 4400 | 3770 | 0.44 0.85 |
| F0 female: reduced body weight gains during precoh- abitation | F0 female: NOEL = 0.4 mg. kg-1 bw/d LOEL = 1.6 mg. kg-1 bw/d | 18.9 mg.L-1 82 mg.L-1 | 58000 (58 µg.g-1) 184000 (184 µg.g-1) | 10 40 | 5800 18400 | 3770 | 0.65 0.2 | ||
| F1: significantly reduced litter sizes and both viability and lactation indices. Reductions in development including delayed eye opening, surface righting, pinna unfolding and air righting reflex. | F1: NOEL = 0.4 mg. kg-1 bw/d LOEL = 1.6 mg. kg-1 bw/d | NA | 57.6 ppm 70.4 ppm | 10 40 | 5760 (5.76 pm) 1760 (1.75 ppm) | 3770 | 0.65 2.14 | ||
| Rat-Oral gavage 42 days precoh- abitation to day 21 of lactation; cross fostering study. Doses 0 and 1.6 mg.kg- 1 bw/d | Argus Research Lab 2000 #418-014 | Maternal: LOEL decrease in body weight gain, reduced gestation time, delivery time and litter size Offspring: LOEL increased mortality, reduced body weight, increased hepatocyte peroxisomes, increased type II pneumo cytes and lamellar bodies in the lung. | Maternal LOEL at dose 1.6 mg.kg-1 bw/d Offspring LOEL at maternal dose of 1.6 mg.kg-1 bw/d (level in liver of offspring at this dose was 70.4 µg.g-1= 70400 µg.kg-1 from study ARL 418-008) | 70400 (70.4 ppm) | 40 | 1760 | 3770 | 2.14 |
a AF of 10 applied for interspecies variability and lab-to-field extrapolation, multiplicative with generic factor of 10 for extrapolation from LOECto NOEC OR study specific factor of 4 where study information was available.
b EEV is maximum concentration of PFOS in Canadian polar bears, South Hudson Bay
Page 15
- Date Modified: